CD8A and neoplasm: VEGF-targeted therapy inhibits the aberrant proliferation of the tumor vasculature and enhances CD8+ T cell infiltration within the TME, while suppressing the activity of immunosuppressive cells, such as TAMs, MDSCs, and Tregs.